General Toxicity Notes
Natriuretic drugs may cause extracellular fluid volume depletion.
Half-Life (Normalesrd) Hours
2-4/4-5
Plasma Protein Binding %
97-99
Volume Of Distribution L/Kg
0.14-0.19
Dose For Normal Renal Function
5-100 mg q12-24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, [D]
References
Dodion L, Willems JL. Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency. Eur J Clin Pharmacol. 1986; 31 Suppl: 49-51. [PMID: 3780839] / Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995; 49: 121-42. [PMID: 7705212] / Friedel HA, Buckley MM. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991; 41: 81-103. [PMID: 1706990] / Gehr TW, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994; 56: 31-8. [PMID: 8033492] / Krö mer BK, Schwab A, Braun N, Strutz F, Mü ller GA, Risler T. Pharmacokinetics of torasemide and its metabolites in end-stage renal disease. Eur J Clin Pharmacol. 1994; 47: 157-9. [PMID: 7859803] / Loute G, Adam A, Ers P, Heremans C, Willems B. The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure. Eur J Clin Pharmacol. 1986; 31 Suppl: 53-5. [PMID: 3780840]
Toxicity Notes
High doses effective in ESRD. Ototoxicity.